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To  empower  governments  to  formulate  rational  policies  without  pressure  from  any  group,  and  to  increase
the  use  of  evidence-based  decision-making  to adapt  global  recommendations  on immunization  to  their
local  context,  the  WHO  has  recommended  on  multiple  occasions  that countries  should  establish  National
Immunization  Technical  Advisory  Groups  (NITAGs).  The  World  Health  Assembly  (WHA)  reinforced  those
recommendations  in  2012  when  Member  States  endorsed  the  Decade  of  Vaccines  Global  Vaccine  Action
Plan  (GVAP).  NITAGs  are  multidisciplinary  groups  of national  experts  responsible  for  providing  indepen-
dent,  evidence-informed  advice  to health  authorities  on all policy-related  issues  for  all  vaccines  across  all
populations.  In  2012,  according  to the WHO–UNICEF  Joint  Reporting  Form,  among  57  countries  eligible
for  immunization  program  ﬁnancial  support  from  the  GAVI  Alliance,  only  9  reported  having  a functional
NITAG.  Since  2008,  the  Supporting  Independent  Immunization  and  Vaccine  Advisory  Committees  (SIVAC)
Initiative  (at the  Agence  de Médecine  Préventive  or AMP)  in close  collaboration  with  the  WHO  and  other
partners  has been  working  to accelerate  and  systematize  the  establishment  of  NITAGs  in  low-  and  middle-
income  countries.  In  addition  to providing  direct  support  to countries  to establish  advisory  groups,  the
initiative  also  supports  existing  NITAGs  to strengthen  their  capacity  in  the  use of  evidence-based  pro-
cesses  for  decision-making  aligned  with  international  standards.  After  5 years  of  implementation  and
based  on lessons  learned,  we recommend  that  future  efforts  should  target  both  expanding  new  NITAGsoutine immunization and  strengthening  existing  NITAGs  in  individual  countries,  along  three  strategic  lines:  (i)  reinforce  NITAG
institutional  integration  to  promote  sustainability  and  credibility,  (ii)  build  technical  capacity  within
NITAG  secretariats  and  evaluate  NITAG  performance,  and  (iii)  increase  networking  and  regional  collabo-
rations.  These  should  be  done  through  the development  and  dissemination  of  tools  and  guidelines,  and
information  through  a variety  of  adapted  mechanisms.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-NDAbbreviations: AMP, Agence de Médecine Préventive; ECOWAS, Economic Com-
unity of West African States; GAVI, Global Alliance for Vaccines and Immunization;
VI,  International Vaccine Institute; JRF, Joint Reporting Form; MoH, Ministry of
ealth; NITAG, National Immunization Technical Advisory Group; NUVI, New and
nder-Utilized Vaccine Introduction; PAHO, Pan-American Health Organization;
IVAC, Supporting Independent Immunization and Vaccine Advisory Committees;
AHO, West African Health Organization; WHA, World Health Assembly; WHO,
orld Health Organization.
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1. Introduction
Following the launch of the Expanded Program on Immuniza-
tion (EPI) by WHO  40 years ago, most low and middle-income
countries began their immunization programs with six anti-
gens: diphtheria-tetanus-whole cell pertussis (DTwP), measles,
oral poliovirus (OPV) and bacillus Calmette-Guerin (BCG). Some
countries subsequently introduced up to ten further antigens,
including hepatitis B, Haemophilus inﬂuenzae type b (Hib) conju-
gate, pneumococcal conjugate (PCV), meningococcal conjugate
(MCV), yellow fever virus, rotavirus, inﬂuenza and human papil-
lomavirus (HPV) [1]. Moreover, several vaccines containing
additional antigens are in the development pipeline (and are likely
to become available in the next decade), such as those containing
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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alaria, dengue, group B streptococcus, tuberculosis, human
mmunodeﬁciency virus and respiratory syncytial virus vaccines.
The immunization arena is also becoming progressively
omplex for a variety of reasons, including the extension of immu-
ization activities beyond childhood; the growing number of
accine manufacturers; the multitude of vaccine presentations;
nd pricing that varies according to supply and demand and (above
ll) the ability to pay.
In addition, national health authorities in many developing
ountries still lack the methodology for evaluating scientiﬁc data
hat is increasingly voluminous and complex. Finally, countries
ith limited ﬁnancial resources are facing even more difﬁcult
hoices when prioritizing recommended public health interven-
ions.
NITAGs are multidisciplinary groups of national experts respon-
ible for providing independent, evidence-informed advice to
ealth authorities on policy-related issues for the entire range of
accines across all populations. The role of NITAGs is to collect,
eview, assess and organize scientiﬁc evidence on speciﬁc vaccine-
elated topics in the form of recommendations to national health
uthorities.
WHO  has repeatedly recommended that countries should estab-
ish NITAGs for two reasons: ﬁrst, to empower governments to
evise logical policies without pressure from any particular out-
ide group; and, secondly, to increase the use of evidence-based
ecision-making for adapting global recommendations on immu-
ization to local contexts. The World Health Assembly (WHA)
olstered these recommendations in 2012 when member states
ndorsed the Decade of Vaccines – Global Vaccine Action Plan
GVAP) [2], a worldwide strategy that aims to prevent millions of
eaths by 2020 via more equitable access to existing vaccines for
eople in all communities. GVAP includes a speciﬁc objective on
ITAGs, namely: “All countries should have a functional NITAG by
020”.
WHO  initially deﬁned six basic indicators for characterizing
unctional NITAGs: formal written terms of reference; a legislative
r administrative status; a minimum of ﬁve main areas of expertise
n the core membership; a meeting at least once a year; a secre-
ariat for distributing the agenda and background material prior
o meetings; and a declaration of interests policy for all members
3]. A more comprehensive set of indicators for assessing NITAG
unctionality, performance, outcomes and outputs was developed
n 2013 by WHO, SIVAC and other partners [4]. The progress made
n this and other objectives will be monitored over the next 10
ears, with an annual report being presented for discussion at the
HA  [2].
NITAGs in developed countries have been instrumental in pro-
iding independent and scientiﬁcally sound advice to governments
or many years. The importance of such NITAGs is illustrated by
he role of the Joint Committee on Vaccination and Immuniza-
ion (JCVI) in the UK, the Advisory Committee on Immunization
ractices (ACIP) in the US, the Vaccine Technical Committee (CTV)
able 1
ountries where SIVAC support was provided or is ongoing/initiated/planned.
NITAG is established Existing NITAG receives strengthening support Establishme
Benin India Burkina Fas
Côte  d’Ivoire Indonesia Ghana 
Kazakhstan Lebanona Guinea 
Kenya  Nepal Lao DPR 
Kyrgyzstan Tunisia Mali 
Mongolia Uganda Nigeria 
Mozambiqueb Vietnam The Gambia
Niger  
Senegal
a Process reinitiated after a suspension.
b Support period completed.33 (2015) 588–595 589
in France, the Standing Committee on Vaccination (STIKO) in
Germany, the Australian Technical Advisory Group on Immuniza-
tions (ATAGI) and the Korea Advisory Committee on Immunization
Practices (KACIP) in South Korea. Other NITAGs from middle-
income countries (such as the Vaccine Technical Committee (CTV)
in Tunisia and the Indonesian Technical Advisory Group on Immu-
nization (ITAGI)) have also reached satisfying operational and
performance levels [5].
According to the WHO-UNICEF JRF, 99 countries worldwide
(52%) in 2012 reported the existence of a NITAG with a formal
(legislative or administrative) basis (with a high of 86% in the
Eastern Mediterranean Region). Among the 63 countries (33%)
that reported having a functional NITAG, only 38 were developing
countries; out of the 57 countries eligible for immunization pro-
gram ﬁnancial support from Gavi, the Vaccine Alliance, only nine
reported a functional NITAG [6].
AMP  and IVI established the SIVAC Initiative in 2008 in close
collaboration with WHO  and backed by funding from the Bill
& Melinda Gates Foundation. SIVAC aims to accelerate and sys-
tematize the establishment of NITAGs in low and middle-income
countries [7]. In addition to providing direct support to countries
for setting up advisory groups, the initiative also helps existing
NITAGs strengthen their capacities to use evidence-based processes
for decision-making with international standards.
As part of AMP’s WHO  Collaborating Center on evidence-
informed immunization policy-making, SIVAC is one of the key
actors supporting WHO-HQ and their regional ofﬁces to establish
and strengthen NITAGs, alongside the US Centers for Diseases Con-
trol and Prevention (US CDC). This group of organizations is heavily
coordinated by WHO-HQ and includes, in particular, the NITAG
focal points from WHO  regional ofﬁces, the US CDC and WHO  IVB.
This paper is devoted to analyzing and discussing SIVAC’s con-
tribution to the WHO  and global community objectives on NITAGs.
We review the lessons learned from the ﬁrst 5 years of the project
and report on the expansion of NITAGs based on SIVAC’s experience
and perspective. We  then present a strategic overview of NITAG
development for the next 5 years.
2. Background
Together with WHO  and partners, the SIVAC initiative has
assisted nine countries in setting up NITAGs since its inception,
and is currently working to achieve the same goal in an additional
eight countries. The initiative has also helped seven countries to
strengthen their pre-existing NITAGs, and agreement for support
has been reached with a further 14 countries over the next 2 years
(See Table 1 and Map  1). The criteria for country selection has been
discussed elsewhere [7,8], as have the methodologies and processes
for establishing NITAGs.
In addition to offering direct assistance to individual NITAGs,
one of SIVAC’s objectives has been to provide global technical
nt or strengthening process is initiated Support process is agreed or planned
o Albania
Armenia
Cambodia
Ethiopia
Malawi
South Sudan
 Tanzania
Zambia
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upport to all countries, including those not directly helped by
he initiative. This includes developing a number of guidelines on
stablishing and operating NITAGs, drawn up in collaboration with
HO  and other partners (such as US Centers for Disease Control
nd Prevention and existing NITAGs). This guidance, which can be
dapted to any country’s health system, provides a framework for
he legal establishment of NITAGs and the preparation of terms
f reference (ToR) and standard operating procedures (SOPs). The
ndia NITAG secretariat, for example, used the guidelines to address
ssues such as managing conﬂicts of interest, limiting external inﬂu-
nce from groups, and deﬁning the roles and responsibilities of
he committee’s members. The guidelines include information on
he mode of operation, the number of members, and the duration
nd number of terms served, as well as the organization of work-
ng groups, interactions with other technical committees such as
ational Regulatory Authorities (NRAs) [9], and the ideal mix  of
xpertise.
. Lessons learned
Amongst the lessons learned, we ﬁrst present the challenges
aced in establishing and strengthening NITAGs since 2008. We
hen set out the perceived beneﬁts that have been reported,
ogether with concrete examples from various countries. We
iscuss all the lessons learned in order to provide the most com-
rehensive context possible.
.1. Challenges
.1.1. National authorities need to better understand the role of
ITAGs
Despite WHO’s multiple recommendations (both globally andegionally) about setting up NITAGs, knowledge about the advisory
roups remains poor among senior immunization health ofﬁcers at
ountry level. In GAVI-eligible countries, the existence of an Inter-
gency Coordination Committee (ICC) is an ofﬁcial requirement forrovided or is ongoing/initiated/planned.
accessing GAVI support. ICCs, which are chaired by the MoH and
comprise the majority of in-country technical partners (e.g. WHO
and UNICEF), focus on implementing EPI decisions made by the
ministry and their operational aspects. NITAGs, on the other hand,
have an advisory role and do not have a mandate to address and
supervise implementation and operations; nor do they concentrate
exclusively on EPI. As a result, the function of the NITAGs does not
overlap or interfere with that of the ICC. In other words, the two
committees should work in complementary fashion.
Lack of knowledge about NITAGs often leads to misconcep-
tions on the part of national authorities, with the independence
of NITAGs being a key concern. In some instances the MoH has
perceived the autonomy of a NITAG as a threat. Ministers and senior
MoH ofﬁcials in one particular eastern European country, for exam-
ple, were afraid that the NITAG might issue recommendations that
would undermine their authority and challenge their prerogatives.
These apprehensions have tended to disappear, however, once the
national authorities have been given further information about the
NITAG’s role as an advisory committee, and have been reminded
that the minister of health appoints NITAG members, assigns the
secretariat, contributes to the agenda and is the ultimate decision-
maker. Concern was also eased when the authorities were shown
examples of NITAGs from other countries.
The secretariat oversees the NITAG agenda in a comprehensive
exercise that involves not only the MoH  but also other national
immunization stakeholders and NITAG members. This approach
ensures that NITAG agendas represent all perspectives [10]. The
independence of recommendations is ensured (i) by obliging vot-
ing members to declare any conﬂict of interest and (ii) by using
systematic evidence assessment to develop the recommendations.
3.1.2. Technical agencies need to better understand the role of
NITAGs in order to facilitate their establishment
It is somewhat surprising that in certain countries and regions
it is the staff of international technical partners, rather than
the national authorities, who have expressed reluctance about
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stablishing NITAGs. There have been concerns that decisions about
ew vaccines could be delayed if it were necessary to consult
ITAGs in advance. Questions have also been asked about the avail-
bility and ability of national experts to make recommendations
hen countries have relied heavily on WHO  and UNICEF for the
ast 4 decades. These concerns result from a lack of understanding
bout the role of a NITAG in the decision-making process. While
onsulting a NITAG may  indeed delay the decision process, it can
easonably be assumed that NITAGs can have strong positive out-
omes over the long run.
Many international partners and technical institutions now sup-
ort the establishment of NITAGs, and recognize their important
ole at country level. All WHO  Regional Committees have recom-
ended that their members create NITAGs. Furthermore, one of
AVI Alliance’s criteria for applications for new vaccine introduc-
ion is whether a country’s NITAG (where applicable) has issued a
ecommendation on the relevant vaccine.
.1.3. Conﬂicting priorities and mistrust impede the
stablishment of NITAGs
The establishment of a NITAG may  be hindered by competing
riorities or mistrust, whether real or perceived. In one east African
ountry, the process of setting up a NITAG (which began with the
ubmission of a letter of intent by senior MoH  ofﬁcers) stalled prior
o the restructuring of the country’s political system in 2010, which
esulted in the creation of two Ministries of Health: a Ministry for
ublic Health and a Ministry for Medical Services. The creation of
he NITAG was subsequently complicated by overlapping portfolios
nd competition between the leadership of the two ministries. In
ddition, the NITAG was not considered to be as high a priority as
ther issues the country was facing.
The government of a certain country in the eastern Mediter-
anean had previously established an advisory group through a
election process that was perceived as biased by other stakehol-
ers. Despite the prominent role played by private immunization
ractitioners, the group did not include any representatives from
he private medical sector. Attempts to reorganize the committee
ere hindered by a lack of trust between the experts from the
rivate sector and the MoH  rooted in two factors: an absence of
ooperation stretching back several decades, and the MoH’s per-
eption that the private sector representatives had strong conﬂicts
f interest with vaccine manufacturers.
.1.4. Scarcity of human resources in secretariats and lack of
raining hamper optimal NITAG functioning
The NITAG’s executive secretariat coordinates NITAG activities
n compliance with their ToR and SOPs. Secretariats are respon-
ible for coordinating the technical background documents for
eview by the committee prior to issuing recommendations. How-
ver, the scarcity of trained human resources in many low and
iddle-income countries hinders the creation of sufﬁciently robust
ecretariats (as is the case for the health sector in general).
Individual countries have adopted different approaches to
tafﬁng NITAG secretariats with varying degrees of success. In one
iddle-income African country, the MoH  appointed the national
PI manager to take on the role of NITAG secretary in addition
o the manager’s routine duties and without providing further
ﬁnancial or human) resources. By contrast, the NITAG executive
ecretariat in one European country is based at the national Cen-
er for Immunoprophylaxis. As well as its public health, training
nd research activities, the center is also responsible for all the
ountry’s immunization-related work and reports directly to the
oH. The entire staff of the center provides support to the NITAG.
 different approach was taken by a country in south-east Asia: the
HO  country ofﬁce initially served as secretariat for the existing33 (2015) 588–595 591
NITAG for several months before responsibility was transferred to
the Child Health Division in the MoH.
It is vitally important that secretariats are fully equipped and
available (under the supervision of the NITAG chair) to conduct
proper assessments of immunization situations, reach consensus,
prioritize agendas items, form working groups and develop com-
munication strategies (targeting government and populations as
required). A visible and physical NITAG secretariat ofﬁce is impor-
tant, together with an email address and other logistical equipment
(such as printers and scanners at the very least).
Based on what has worked well in NITAGs in developed
countries, an executive secretariat would ideally be housed in a
national research institution with a dedicated and experienced
immunization professional (preferably a public health physician);
he or she would be assisted by at least one full-time junior mem-
ber with a public health (or related) master’s degree. The institution
would have perfect communication channels with the EPI program
manager and the authority to call on any academic personnel as
required.
It is a given that all NITAG secretariats eventually reach limits in
terms of their expertise and overall stafﬁng, and that this can hinder
adequate preparation for meetings, such as drawing up background
technical materials and distributing documents in advance. Sev-
eral NITAGs have overcome these limitations through the extensive
use of technical working groups, which typically include one or
two NITAG members, the NITAG executive secretariat, and national
experts (external to the NITAG) who  assemble scientiﬁc content
prior to full NITAG meetings. The value of such groups has been
illustrated in numerous countries: in Tunisia, for example, a speciﬁc
working group on pneumococcal conjugate vaccine was  estab-
lished to gather international evidence and, more importantly, to
explore the availability of local, unpublished data. After the group’s
ﬁndings were presented, NITAG members requested that further
data be collected focusing on the potential economic implications
of reduced hospitalizations due to vaccination. The replicability of
this model requires access to local experts and strong coordination
skills.
A critical need emerged, whilst helping countries to create or
improve their NITAGs, for capacity building in setting up com-
mittees. During the training on roles and responsibilities in some
Asian and African secretariats, SIVAC identiﬁed the imperative to
strengthen the following areas: preparing background material,
coordinating working groups, using recognized methodologies to
assess the quality of evidence, and developing structured recom-
mendations. SIVAC and its international partners are now drawing
on these early experiences to provide similar training to secre-
tariats in several countries where the NITAGs are considering IPV
introduction in Europe and Africa.
3.1.5. Lack of national experts impedes the establishment and
functioning of NITAGs
WHO  recommends that NITAG core members should represent
at least ﬁve different areas of expertise [3], and the availability
of local experts is one of the most important factors considered
by SIVAC when analyzing a country situation. Established training
institutions (recognized universities), hospitals (mostly university
hospitals) or research bodies (e.g. Pasteur Institutes) have existed
for several years in all the countries where NITAGs have been set up
or strengthened. As well as providing a source of expertise, these
establishments enhance the credibility of the recommendations
issued by a NITAG.
A mapping exercise should be carried out as soon as a NITAG is
created to identify national researchers and experts by specialty,
ﬁeld of research, etc. The secretariat should then plan an infor-
mation strategy on the NITAG’s role and mission together with
an outline of the type of support it may  require. A mechanism
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or ensuring efﬁcient cooperation and collaboration should also be
ntroduced. National experts are usually more than willing to offer
heir support provided that requests are clearly formulated with
easonable timelines.
With their greater NITAG managerial and operational expertise,
nternational and national agencies play a pivotal role, as do techni-
al partners. They help to ensure that NITAG recommendations take
nto account the realities of a country on the ground, such as gov-
rnment priorities or the requirements of funders. Moreover, their
articipation in NITAG meetings avoids the perceived split between
cademics and “implementers”. This combination of skills and roles
ithin a NITAG has been viewed very positively by countries and
s to be encouraged.
.1.6. The absence of a proper management of conﬂicts of interest
hreatens the independence of recommendations
One of the challenges in almost all SIVAC-supported countries
as been to convey that NITAG recommendations must be indepen-
ent of all external inﬂuences: not just from vaccine manufacturers
ut also from the MoH  and WHO. One way to achieve this goal
s by managing potential conﬂicts of interest in a transparent
anner.
A conﬂict of interest involves a clash between an ofﬁcial’s pub-
ic duty and private-capacity interests, in which the latter could
mproperly inﬂuence the performance of his or her functions and
esponsibilities [6]. NITAG members who have a conﬂict of interest
ith vaccine producers are either requested to leave the room dur-
ng discussions in which they have a declared interest or are asked
o withhold from voting. An additional concern has been that mem-
ers might be inﬂuenced by external groups even when no conﬂict
f interest currently exists. Where this has been the case, NITAGs
ave consulted with peers from developed countries on an indi-
idual basis. There is, however, no generic way of handling such
ituations.
As liaison and ex-ofﬁcio members, WHO  and MoH  representa-
ives do not normally vote.
Despite initial worries, the systematic use of conﬂict of interest
orms in SIVAC-supported countries has been accepted and has led
o improved trust between stakeholders.
.1.7. Lack of solid institutional integration threatens ﬁnancial
ustainability and resistance to political turmoil
Although the ﬁnancial requirements for operating NITAGs on an
n-going basis are limited (logistics for meetings, occasional con-
ultancy fees and domestic travel for members), the early years
equire substantial resources, mainly for building technical capac-
ty. MoH  reserves are ﬁnite, and plans are not always in place to
nsure that committees continue functioning when initial fund-
ng comes to an end. In two countries, the recognition of NITAGs
s formal advisory committees by the MoH  (and other stakehol-
ers) has proved vital for securing domestic funding. Two  other
ITAGs in Asia and Eastern Europe secured government funding
nly once SIVAC ﬁnancial support ceased; NITAG activities were
hen included in the MoH  annual work plan.
However, MoH  recognition does not guarantee funding. For
xample, two African and Asian countries are yet to obtain on-going
nancing for their activities. As a result, the 2 years of ﬁnancial and
echnical support initially planned by SIVAC have been extended
o prepare for long-term sustainability, mainly by helping the MoH
o include an additional line in the regular budget.
There was also an unfortunate situation in one African coun-
ry, where the per diem received by NITAG members was  too high
in spite of SIVAC’s strong opposition to such practices), and the
ITAG failed to secure government ﬁnancing when SIVAC support
ame to an end. In addition, although resources for NITAG opera-
ions were integrated into the Health System Strengthening (HSS)33 (2015) 588–595
application submitted to GAVI in 2012, the proposal was rejected.
Consequently, the NITAG failed to carry out any activities in
2013.
NITAGs that have been fully integrated into the immunization
system are able to continue functioning when external factors,
such as political turmoil, intervene. Revolutions or civil wars broke
out in several countries during the NITAG implementation phase
(Kyrgyzstan (2010), Tunisia (2011) and Côte d’Ivoire (2012)). As a
result, the planned NITAGs could not be implemented, and existing
NITAGs suffered interruptions to their activities.
However, in countries where NITAGs were properly inte-
grated into the national public health system, they withstood the
upheaval. In Côte d’Ivoire, for example, the newly-formed NITAG
ceased operating during the political crisis that followed the pres-
idential elections, but was  able to resume very rapidly owing to
the high motivation of NITAG core members. While not yet opti-
mal  in every aspect, the Côte d’Ivoire committee is active and has
issued recommendations. An equally positive example was  seen
in Tunisia during the 2011 turbulence, when the NITAG contin-
ued to meet regularly despite the rapid turnover of senior health
ofﬁcials. The legislative laws that created the NITAGs in Tunisia
and Côte d’Ivoire facilitated their sustainability in a time of great
crisis.
3.2. Opportunities and successes
3.2.1. New NITAGs have impacted on recent vaccine decisions
A vivid example of a NITAG inﬂuencing a vaccine decision was
seen in 2012, when the MoH  in a certain African country was
preparing to apply for GAVI Alliance funding for rotavirus vaccine
(through the Immunization Coordination Committee (ICC)). Fol-
lowing the MoH’s decision, the NITAG reviewed the proposal and
found that the local epidemiological data used to justify the choice
of vaccine was incomplete. The NITAG then requested the analy-
sis of additional data that had been collected over several years
by national research institutes. The MoH  took heed of the NITAG’s
advice, delayed the submission of the application and requested
that the NITAG examine the supplementary data. Based on a com-
bination of the evidence reviewed as part of the initial application
(epidemiological, economic, logistical, etc.) and the additional data,
the country decided to introduce a different rotavirus vaccine.
NITAGs include a number of new but important stakeholders in
the immunization decision-making process that are not involved
in ICCs, such as academics and health care professionals, scientiﬁc
societies and NGOs, and representatives from civil society. It is not
surprising, therefore, that NITAGs can be perceived as a disruptive
inﬂuence. However, the slight delays that may  result from NITAG
involvement are counterbalanced by the beneﬁts of more robust,
evidence-based decisions that are tailored to local speciﬁcities. Fur-
thermore, as all national immunization stakeholders are (ideally)
represented on NITAGs, their recommendations are more likely to
be accepted – and implemented – by MoH, especially if there is an
effective NITAG communication strategy. Finally, the involvement
of NITAGs in the decision-making process ensures that recommen-
dations are widely disseminated.
There is no disputing that the intervention of independent com-
mittees in high-income countries may  result in short delays in
vaccine introduction. However, it is hoped that by pooling the
efforts of all partners, NITAGs in low and middle-income countries
may  attain similar levels of trust and credibility. Secretariats should
remember that, as the scope of a NITAG is not restricted to new
vaccines, their agendas should be wide-ranging and include (for
example) routine immunization, vaccine hesitancy and surveil-
lance alerts. In short, NITAG recommendations should focus on
immunization systems in their entirety when making recommen-
dations.
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.2.2. Experience sharing with other NITAGs provides good
earning opportunities
Orientation and training sessions are held shortly after the
stablishment of a new NITAG to help secretariat members under-
tand their roles and the functioning of the NITAG. SIVAC has
ffered support to secretariats for attending the meetings of efﬁ-
ient, long-existing NITAGs. For example, the chair and secretary
f the Nepal NITAG has visited the Australian NITAG (ATAGI),
nd two representatives from the Côte d’Ivoire and Lebanon com-
ittees paid a visit to the French NITAG (CTV). In both cases,
he visiting NITAG members valued the opportunity to discuss
heir experiences in person with other NITAGs and to observe
eetings.
The impact of such experience sharing has been particularly
oticeable in Tunisia and Mongolia. Following a visit to the Quebec
tate committee, the Tunisian NITAG conducted an in-depth reor-
anization of its processes and technical activities (i.e. preparation
f background materials, use of working groups, and development
f meeting agendas). Similarly, after two ofﬁcials from Mongolia
ttended the New Zealand Immunization Technical Forum (an advi-
ory body to the New Zealand MoH), the Mongolian government
ssued a decree altering the NITAG membership structure (adding
x-ofﬁcio and liaison members); started using working groups to
repare materials for NITAG meetings; and initiated a discussion
n ﬁnancial sustainability. Finally, after delegates from an eastern
uropean country attended the European Technical Advisory Group
f Experts (ETAGE) in 2012, its NITAG membership was  revised, and
he chairperson – an MoH  ofﬁcial – stepped down, to be replaced
y an independent chair from academia.
.2.3. Partnering with local and regional organizations has been a
uccess
Strategic collaborations have been instrumental in promoting
he creation of NITAGs, particularly in the Asian and West African
egions. ECOWAS ministers issued two recommendations to mem-
er states in 2012 and 2013 to set up NITAGs [11], which saw
ITAGs being established in Benin, Senegal and Niger, as well as
reliminary steps in more than ten West African countries, includ-
ng Nigeria, Liberia, Gambia, Mali, Guinea, Togo and Burkina Faso
12]. WAHO regional support played a key role in introducing these
ountries to the process of creating a NITAG [12].
.2.4. Global availability of technical resources facilitates NITAG
unctioning
A wide-ranging consultation in 2009 among national stakehol-
ers and technical partners at country and global level concluded
hat relevant information should be made available to all countries
ishing to establish or strengthen a NITAG. It was recommended
hat an extensive, multilingual, online database for NITAG members
nd secretariats be set up. This online tool, which was launched
009, includes [5]:
A NITAG observatory for providing technical guidelines on the cre-
ation and functioning of NITAGs, and information on more than 50
NITAGs around the world, including examples of their recommen-
dations.
A digital library.
A Center of Expertise, which features vaccinology courses and
trainings.
NITAG members from Tunisia and Mozambique reviewed
he online tool with partners in an independent evaluation in
ecember 2012. The resources were rated as being highly effective,
specially the observatory and online library. However, according
o the tracking tools, some of the Center of Expertise modules (the
-learning component in particular) could be improved by adding33 (2015) 588–595 593
more documentation on NITAGs and vaccines. As a consequence,
the e-learning component will be revised and a new tool launched
in 2014.
3.2.5. A step-by-step, country-driven approach to establishing
and/or strengthening NITAGs is indispensable
While the aim is to implement best practice guidelines for all
SIVAC countries, the approach to establishing or strengthening a
NITAG is unique to each setting. Local contexts and speciﬁcities
make it impossible to employ the same processes everywhere and
at every step, such as:
Obtaining initial ministry support.
Analyzing the country’s immunization context and adapting
guidelines to the speciﬁc situation.
Supporting the development of a NITAG concept paper and the
drafting of a ministerial decree.
Conducting training for committee members on their roles and
responsibilities.
Providing technical training to the secretariat.
In some countries the existence of other immunization commit-
tees, a strong private sector or two MoH  have made it impossible
to employ the same mechanisms. For the approach to be country-
driven, it is crucial to have the support of the MoH: where a ministry
has been convinced of the added value of a NITAG, it has been
established successfully. In short, by using a step-by-step, country-
driven approach, most obstacles can be overcome.
3.2.6. Developed countries reported a positive impact from SIVAC
activities
A number of developed countries have reported changing some
NITAG features based on SIVAC’s experience of establishing NITAGs,
with Israel offering the following concrete example.
The Israeli Advisory Committee on Infectious Diseases and
Immunizations (established 40 years ago) has 15 core members,
nine ex-ofﬁcio members and six observers, all appointed by the
Director of Public Health Services in the MoH. The committee was
reformed after examining the April 2010 Vaccine supplement [3]
describing the structure and functions of a NITAG. The 2012 reform
was approved by the MoH  and impacted the committee in the fol-
lowing areas:
Term of ofﬁce: previously unlimited, this is now restricted to 5
years (possible to add further terms).
Membership categories: now includes three groups – core mem-
bers, ex-ofﬁcio members and observers.
Voting rights: the Vaccine articles generated debate about the vot-
ing rights of ex-ofﬁcio members, who ultimately retained their
right to vote.
Terms of reference: a more detailed document is now in place.
Conﬂict of interest policy: a policy was  adopted and new forms
developed.
Types of expertise: an economist and legal adviser were appointed
as observers.The functioning of the committee has improved with the reform,
and a self-assessment of its effectiveness (based on WHO  indica-
tors) is planned for 2014 [4].
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using NITAGs. By adopting the GVAP, all countries are commit-
ted to setting up NITAGs, meaning that many states will need to94 A. Adjagba et al. / Va
. Implications and recommendations for creating and
trengthening future NITAGs
.1. Reinforce institutional integration to promote sustainability
nd credibility
NITAGs that are fully integrated into a country’s health system
eneﬁt from sustainability and credibility, with two decisive factors
eing: the careful positioning of the NITAG in the decision-making
rocess; and a legal (ministerial or legislative) establishment docu-
ent. Institutional integration can also be facilitated by addressing
isconceptions and misunderstandings about the role and respon-
ibility of NITAGs. This requires open communication from all
artners at country-level in order to avoid sending confusing mes-
ages to health authorities.
Institutional integration may  also involve coordination with
ther disease-speciﬁc advisory committees. NITAGs are expected
o provide technical advice on all immunization-related aspects
including new vaccines and routine immunization) and to recom-
end ways to improve the overall operation of the immunization
ystem. Accordingly, their interactions with existing vaccine-
peciﬁc committees and routine immunization programs require
lariﬁcation. Many GAVI-eligible and middle-income countries
ith well-functioning, disease-speciﬁc committees (such as polio,
easles or hepatitis committees) increasingly support the estab-
ishment or strengthening of NITAGs.
Future efforts should include activities aimed at integrating
isease-speciﬁc advisory committees into NITAGs; reinforcing
nstitutional positioning; and increasing compliance with WHO-
ecognized practices in terms of technical methodologies for
ollecting and assessing evidence for generating recommendations.
As we have seen, institutional integration allows NITAGs
o withstand political turmoil, facilitates ﬁnancial security and
nhances credibility. It bears repeating that, in all SIVAC-supported
ountries that have experienced political upheaval, NITAG activi-
ies resumed thanks to the legal standing of the committee and
he NITAG’s solid integration into a pre-existing institution. Fur-
hermore, it is easier for NITAGs with institutional integration (and
hich, therefore, beneﬁt from broad acceptance) to secure funding
nd ensure sustainability after external support has ended. Ade-
uate funding is, of course, of paramount importance: NITAGs must
evelop plans that focus on the most sustainable sources of ﬁnance
although government backing remains the ideal source).
.2. Build technical capacity within NITAG secretariats and
valuate performance
A study of the 2012 WHO–UNICEF JRFs found that NITAGs need
o comply with international standards. Out of 63 countries that
eported having a NITAG, only 33% met  the six process indicators
f an efﬁcient NITAG [6], whereas the GVAP objective for 2020 is
hat all countries should have fully-functional NITAGs. These results
eveal the need to strengthen both new and existing NITAGs. Future
fforts should focus on building the technical capacities of NITAG
xecutive secretariats so that they have adequate resources to carry
ut their responsibilities; this is the key to optimal functioning for
ll NITAGs and especially for those that have recently been created.
The need to provide organizational support and capacity build-
ng for NITAG secretariats and members (including clear ToR and
OPs) is widely accepted. Additionally, technical partners may  play
 fundamental role in ensuring that nascent NITAG secretariats
ollate appropriate evidence and follow standard procedures. Tech-
ical support requires the development of normative documents by
HO  and relevant partners (e.g. guidelines for issuing evidence-
ased recommendations, including methodologies for the critical
ssessment of evidence and compiling recommendation briefs).33 (2015) 588–595
It also calls for in-person training on important topics such as
mapping immunization stakeholders, the functioning of working
groups, the use of accepted methodologies to assess scientiﬁc evi-
dence, and methodologies for writing policy briefs.
A signiﬁcant milestone for established and newly-created
NITAGs alike is the assessment of their outputs and outcomes.
This assessment can be performed by the MoH  itself or an exter-
nal consultant using the 17 output and outcome indicators deﬁned
by WHO  [4]. SIVAC and partners used these criteria to develop a
full evaluation protocol, including guidance for the desk review of
NITAG documents, and an analysis plan. The protocol, which was
piloted recently in Mongolia, Côte d’Ivoire, Nepal and Indonesia,
is currently being revised and ﬁnalized; it will be made publicly
available on the NITAG Resource Center. For existing NITAGs, the
assessment should be conducted prior to developing the work
plan in order to identify weaknesses regarding functionality and
performance indicators, and to allow for a plan to be drawn up
in accordance with the requirements that are identiﬁed. Findings
from these evaluations will be presented in a future joint publica-
tion on NITAG production, impact and performance.
4.3. Increase networking and regional collaboration
Executive secretariats should develop ties with other NITAGs
to ensure their continued development. For example, as described
above, interaction with strong NITAGs can have a rapid impact on
nascent NITAG functioning and performance.
Networks can be established based on WHO  regions or other
similarities, such as language. For instance, in the Eastern Mediter-
ranean Region, the Tunisian NITAG could help form a regional
network with Sudan, Morocco, Iran and Egypt in collaboration
with the WHO  Regional Ofﬁce. In sub-Saharan Africa, one network
could bring together French-speaking NITAGs, and another their
English-speaking equivalents, with a third for Portuguese-speaking
Angola, Mozambique, Cape Verde and Guinea Bissau. Other poten-
tial regional networks could include Vietnam, Lao DPR, Cambodia
and the Philippines in the Western Paciﬁc region, as well as the
countries of eastern European.
5. Conclusions
A number of immunization initiatives, including SIVAC, have
contributed to the increased use of evidence-informed decision-
making on immunization at country level over recent years. Low
and middle-income nations have relied heavily on external author-
ities for policy advice, yet vaccine recommendations need to be
adapted to local contexts. Despite interest in evidence-informed
decision-making in many countries, technical assistance is still
required to promote a sustainable and independent body that
can advise governments on the local application of global vaccine
recommendations. International and national technical agencies
should also play a more active role in NITAGs as liaison members.
This combination of skills and roles has proved highly success-
ful and helped NITAGs to avoid issuing recommendations that are
“unrealistic” or “too theoretical”.
Based on the lessons learned over the last 5 years, advo-
cacy will be required from all immunization partners to help
raise awareness about the importance of evidence-based policiesestablish or strengthen their NITAGs. The process of setting up a
NITAG should be more straightforward in these countries, given
the methodology and resources now accessible to all regions in
need.
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Efforts should concentrate on expanding new NITAGs and
trengthening existing ones in individual countries as well as
eveloping a regional approach (where relevant); devising and dis-
eminating tools and guidelines; and sharing information through
 variety of channels. Signiﬁcant time, effort and money need to be
nvested in strengthening NITAG secretariats, particularly as some
ITAGs may  not have the experience and institutional stability to
ontinue in the absence of additional technical support.
While solutions to some of these problems already exist,
ountries still need to take an active role in establishing and main-
aining NITAGs. Although WHO  will continue to function as the lead
echnical organization, its leadership should not impede NITAG
ndependence provided that the following conditions are met: the
oR, positioning and funding are clear; there is a solid and well-
quipped secretariat; the processes are rigorous; and members
ave strong technical capacities.
As part of the WHO  Collaborating Center for evidence-informed
olicy-making in immunization, SIVAC will continue to work
n collaboration with WHO  to support NITAG development and
trengthening. GAVI Alliance, for its part, could require a plan for
ITAG development for HSS funding and support its implementa-
ion. Countries should also investigate innovative mechanisms to
ustain funding for NITAGs. Without an accelerated and joint effort,
he GVAP objective of “all countries having a functional NITAG by
020” will not be achieved.
onﬂict of interest statement
The SIVAC Initiative forms part of a separate legal entity within
MP; it receives no support from any vaccine manufacturers. The
IVAC Initiative is entirely funded by a grant from the Bill & Melinda
ates Foundation.
cknowledgementsWe would like to express our appreciation to Dr Juliane Chac-
our and Dr Antoinette Ba-Nguz for reviewing this paper and
roviding helpful comments. Particular thanks are also due to our33 (2015) 588–595 595
WHO  colleagues, especially Dr Philippe Duclos from WHO  HQ, and
all staff from regional ofﬁces involved with NITAG strengthening
for sharing their practical experience.
References
[1] Chan M.  Beyond expectations: 40 years of EPI. Lancet 2014;383(May
(9930)):1697–8.
[2] World Health Organization Global Vaccine Action Plan; 2014. Available
at:  http://www.who.int/immunization/global vaccine action plan/GVAP doc
2011 2020/en/ [accessed 10.06.14].
[3] Duclos P. National Immunization Technical Advisory Groups (NITAGs): guid-
ance for their establishment and strengthening. Vaccine 2010;28(Suppl.
1):A18–25.
[4] Blau J, Sadr-Azodi N, Clementz M,  Abeysinghe N, Cakmak N, Duclos P, et al. Indi-
cators to assess National Immunization Technical Advisory Groups (NITAGs).
Vaccine 2013;31(23):2653–7.
[5] SIVAC Initiative NITAG Resource Center; 2014. Available at:
http://www.nitag-resource.org/en/home/index-home.php [accessed
10.06.14].
[6] Duclos P, Dumolard L, Abeysinghe N, Adjagba A, Janusz CB, Mihigo R,
et  al. Progress in the establishment and strengthening of National
Immunization Technical Advisory Groups: analysis from the 2013
WHO/UNICEF joint reporting form, data for 2012. Vaccine 2013,
http://dx.doi.org/10.1016/j.vaccine.2013.08.084, pii:S0264-410X(13)01196-1.
[7]  Senouci K, Blau J, Nyambat B, Coumba Faye P, Gautier L, Da Silva A, et al. The Sup-
porting Independent Immunization and Vaccine Advisory Committees (SIVAC)
Initiative: a country-driven, multi-partner program to support evidence-based
decision-making. Vaccine 2010;28(Suppl. 1):A26–30.
[8] Blau J, Faye PC, Senouci K, Dagnan SN, Douba A, Saracino JT, et al. Establishment
of  a National Immunization Technical Advisory Group in Côte d’Ivoire: process
and lessons learned. Vaccine 2012;30(15):2588–93.
[9] Chocarro L, Duclos P, Senouci K, Southern J. Consultation on interactions
between National Regulatory Authorities and National Immunization Technical
Advisory Groups. Expert Rev Vaccines 2011;10(9):1265–70.
10] SIVAC Initiative NITAG Resource Center; 2014. Available at:
http://www.nitag-resource.org/en/digitallibrary/search.php [accessed
10.10.14].
11] Western Africa Health Organisation Programme of Work – Health
Experts Meeting 1–2 April 2013, Praia, Cape Verde; 2013. Available
at:  http://www.wahooas.org/IMG/pdf/Programme of Work - Experts.pdf
[accessed 10.06.14].Wachsmuth I, et al. Accelerating the development of National Immunisation
Technical Advisory Committees in West African countries: role of a regional
integration organisation, the West African Health Organisation. Int J Behav
Healthcare Res 2015 [in press].
